Active Biotech AB Interim report January - March 2016
April 28 2016 - 1:30AM
Laquinimod
· The clinical Phase 3 study CONCERTO, 0.6 mg/day, in
relapsing remitting multiple sclerosis (RRMS), with the aim to
obtain market approval in the US and Europe, is proceeding
according to plan. Study results are expected in the first half of
2017
· The clinical Phase 2 study ARPEGGIO for the treatment of
primary progressive multiple sclerosis (PPMS) is proceeding
according to plan
· The clinical Phase 2 study LEGATO-HD for the treatment of
Huntington's disease is proceeding according to plan
· Extension studies with 0.6 mg laquinimod in patients from
the Phase 3 studies ALLEGRO and BRAVO are proceeding according to
plan
· As earlier communicated the highest dose groups in the
clinical studies CONCERTO, ARPEGGIO and LEGATO-HD have been
discontinued due to cardiovascular events
Tasquinimod
· In March 2016, it was announced that the company plans to
develop tasquinimod to treat multiple myeloma and intends to seek a
collaboration partner for the project
· An expanded analysis of the secondary endpoints in the
10TASQ10 study was presented at the ASCO GU Symposium in January
2016. The results showed that tasquinimod had positive effects on
both radiographic and PSA-based endpoints. However, as previously
communicated, overall survival (OS) was not extended, prompting the
discontinuation of all further development within prostate
cancer
ANYARA, Paquinimod (57-57)
and SILC (ISI)
· Out-licensing activities are continuing
Financial summary
MSEK |
Jan. - Mar. |
|
Full
Year |
|
|
2016 |
2015 |
|
2015 |
|
|
|
|
|
|
|
Net sales |
3.9 |
2.9 |
|
16.3 |
|
|
|
|
|
|
|
Operating loss |
-16.1 |
-57.4 |
|
-177.9 |
|
|
|
|
|
|
|
Loss for the period |
-16.8 |
-58.0 |
|
-193.5 |
|
|
|
|
|
|
|
Loss per share, before and after dilution
(SEK) |
-0.19 |
-0.64 |
|
-2.15 |
|
|
|
|
|
|
|
Cash and cash equivalents (at the end of the
period) |
76.5 |
270.5 |
|
103.6 |
|
For further information, please
contact:
Tomas Leanderson, President and
CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 05
The report is also available at www.activebiotech.com.
Active Biotech AB (publ) Interim
report January - March 2016
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
HUG#2007548
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2024 to May 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Actividentity Corp (MM) (NASDAQ): 0 recent articles
More Active Biotech News Articles